105 results about "Hemagglutinin" patented technology

The invention discloses a kit, an antibody and a method for detecting A-type botulinum toxin hemagglutinin-70. The kit of the present invention comprises an antibody capable of targeting type A botulinum toxin hemagglutinin-70. The antibody disclosed by the invention has good affinity and stability, can be widely applied to detection of A-type botulinum toxin hemagglutinin-70, can be combined with a capillary immunoelectrophoresis method to establish a standard map for detecting botulinum toxin component antibodies, and provides a quality control means for commercialized and self-researched antibodies, so that the antibody has good application prospects. According to the method, more possibilities are provided for establishment of related botulinum toxin detection methods, and detection requirements of more scenes can be met.

The present disclosure is directed to peptide antigens derived from a previously undefined epitope on influenza A virus hemagglutinin and methods for use thereof.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The present invention is inter alia directed to immunogenic compositions comprising: (a) a first hemagglutinin (HA) antigen or a first nucleic acid, suitably mRNA, encoding the first HA antigen wherein the first HA antigen is derived from a strain of Influenza virus; and (b) a second HA antigen or a second nucleic acid, suitably mRNA, encoding the second HA antigen wherein the second HA antigen is derived from a strain of Influenza virus, wherein (a) and (b) are different, and wherein the ratio of (a):(b) is comprised between 1.5:1 and 5:1. The present invention is also directed to vaccines and kits or kits-of-parts comprising such. Immunogenic compositions, vaccines and kits-of-parts provided herein are suitable for use as a medicament, in particular, for use in the treatment or prophylaxis of an infection with an Influenza virus, suitably an Influenza A and / or Influenza B.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to methods for preparing viral proteins, such as influenza hemagglutinin proteins and / or influenza neuraminidase proteins, immunogenic compositions comprising the viral proteins thus obtained and vaccines comprising the same, as well as methods of using the same, in particular in the prevention and / or treatment of diseases or conditions caused by viruses, such as influenza viruses.

This application relates to modified H5 influenza hemagglutinin polypeptides and messenger ribonucleic acids (mRNAs) encoding the same, as well as compositions and vaccines comprising the same and methods of using the same, such as in the prevention and / or treatment of diseases or conditions caused by influenza A viruses, particularly influenza A virus, subtype H5, such as H5N8 or H5N1.

The invention belongs to the technical field of biological medicines, and particularly relates to a dissociation liquid applied to an aluminum adjuvant adsorption influenza vaccine and a method for measuring the antigen content. The dissociation liquid disclosed by the invention is prepared from a potassium phosphate salt solution, diethanol amine, TritonX-100, tween-20, dodecyl dimethyl betaine and water. The dissociation liquid is excellent in dissociation efficiency, the dissociation recovery rate of the dissociation liquid to H1N1, H3N2 and BV type influenza vaccine hemagglutinin reaches 106%-110%, the antigen activity can be effectively protected, operation is easy and convenient, adaptability is wide, a dissociated sample can be directly used for mainstream detection methods such as a one-way immunodiffusion test, an enzyme-linked immunosorbent assay and a high performance liquid chromatography method, and the dissociation liquid has good application prospects. The precise quantification of the antigen content in the aluminum adjuvant adsorption influenza vaccine is realized, and a reliable technical support is provided for vaccine quality control.

To provide a method for stably and efficiently producing a protein in secretory production of a target protein using BEVS.SOLUTION: The present invention also provides a method for producing a fusion protein, comprising the steps of expressing the fusion protein in cultured insect cells using a recombinant baculovirus comprising a polynucleotide encoding the fusion protein, and recovering the fusion protein from the culture supernatant, wherein the fusion protein is derived from silkworm H1N1 influenza virus hemagglutinin or silkworm osteonectin.SELECTED DRAWING: None

The present invention relates to a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more stem domain sequences fused to one or more globular head domain sequences, each of the one or more stem domain sequences having at least 60% homology to a stem domain consensus sequence of an H1 subtype HA (H1 HA) and / or an H5 subtype HA (H5 HA), each of the one or more globular head domain sequences having at least 60% homology to a globular head domain consensus sequence of an H1 subtype HA (H1 HA) or an H5 subtype HA (H5 HA).

This invention discloses a neutralizing antibody against influenza A virus and its applications. The neutralizing antibody has a heavy chain and a light chain. The heavy chain comprises heavy chain CDR1 (amino acid sequence as shown in SEQ ID NO:5), heavy chain CDR2 (amino acid sequence as shown in SEQ ID NO:6), and heavy chain CDR3 (amino acid sequence as shown in SEQ ID NO:7); the light chain comprises light chain CDR1 (amino acid sequence as shown in SEQ ID NO:8), light chain CDR2 (amino acid sequence as shown in SEQ ID NO:9), and light chain CDR3 (amino acid sequence as shown in SEQ ID NO:10). The antibody of this invention exhibits highly efficient and broad-spectrum neutralizing activity against influenza A virus, and can bind to multiple subtypes of hemagglutinin, inhibiting the cleavage of hemagglutinin precursor proteins and conformational changes of hemagglutinin in acidic environments. This invention has significant implications and promising applications for the prevention and treatment of diseases caused by influenza A virus.

This application discloses a recombinant hemagglutinin protein, its uses, expression methods, and subunit vaccines, belonging to the field of biomedical technology. The technical solution is as follows: a recombinant hemagglutinin protein, obtained by removing the transmembrane and intracellular regions of the HA protein sequence of the H7N9-235 strain and fusing a T4-foldon sequence at the C-terminus; or by retaining the full-length sequence of the HA protein of the H7N9-235 strain. The amino acid sequence of the recombinant hemagglutinin protein is shown in SEQ ID NO.1 or SEQ ID NO.2. The application also discloses a recombinant hemagglutinin protein with good immunogenicity and medical prospects based on the H7N9 strain. Furthermore, when a subunit vaccine is prepared using the recombinant hemagglutinin protein with the transmembrane and intracellular regions removed, the immunogenicity after secondary immunization is significantly enhanced.

This invention discloses a targeted adjuvant influenza vaccine composition for atrial fibrillation patients with atrial fibrosis. The vaccine antigen components are selected from the surface antigens of currently prevalent influenza virus strains, such as hemagglutinin (HA) and neuraminidase (NA). High-purity influenza virus antigens are prepared through cell culture or recombinant DNA technology. For example, influenza virus is cultured using Madin-Darby canine kidney (MDCK) cells, and purified through centrifugation, filtration, and chromatography to obtain high-purity HA and NA antigens. After injection into the human body, the influenza virus antigens (HA and NA) are taken up and processed by antigen-presenting cells (such as macrophages and dendritic cells). The antigen-presenting cells present antigen peptides to T lymphocytes and B lymphocytes, activating a specific immune response. B lymphocytes differentiate into plasma cells with the help of T lymphocytes, producing specific antibodies that recognize and bind to the influenza virus, preventing it from infecting host cells and thus preventing influenza virus infection.

The application discloses a kit, an antibody and a method for detecting botulinum toxin type A hemagglutinin-70. The kit comprises an antibody capable of targeting botulinum toxin type A hemagglutinin-70. The antibody has good affinity and stability, can be widely applied to detection of botulinum toxin type A hemagglutinin-70, and can combine with a capillary immunoelectrophoresis method to establish a standard atlas for detection of botulinum toxin component antibodies, and provide a quality control means for commercialized and self-developed antibodies. Therefore, the application provides more possibilities for establishment of a botulinum toxin related detection method, and can meet detection requirements of more scenes.

The present invention relates, in particular, to an immunogenic composition for use in the treatment or prevention of infection by influenza virus. The immunogenic composition comprises (a) a first nucleic acid encoding the hemagglutinin (HA) antigen of a strain of a first subtype of influenza A virus, (b) a second nucleic acid encoding the HA antigen of a strain of a second subtype of influenza A virus, (c) a third nucleic acid encoding the HA antigen of a first strain of influenza B virus, and (d) a fourth nucleic acid, optionally included, encoding the HA antigen of a second strain of influenza B virus, wherein the immune response is induced against the aforementioned strains of the first and second subtypes of influenza A virus, the aforementioned first strain and optionally included second strain of influenza B virus, and the HA antigen of at least one further HA antigen subtype of influenza A virus (different from any of the HA antigen subtypes of influenza A virus encoded by the nucleic acids present in the composition). [No selection diagram available]

Provided herein are nucleoside-modified ribonucleic acid molecules encoding a chimeric influenza virus hemagglutinin (HA) polypeptide that comprises a HA globular head domain and a HA stalk domain, wherein the HA stalk domain comprises an amino acid sequence of a HA stalk domain of an influenza B, the HA globular head domain comprises an amino acid sequence of a HA globular head domain of an influenza A, or the HA globular head domain comprises an amino acid sequence of a HA globular head domain of the influenza B, wherein one or more antigenic sites have been replaced with antigenic sites of an influenza A, and the nucleoside-modified RNA molecule comprises at least one pseudouridine. Also provided herein are methods of immunizing a subject against influenza virus disease and methods of preventing influenza virus symptoms in a subject using a composition described herein.

To provide a universal vaccine effective against a wide range of influenza virus strains.SOLUTION: The present invention provides a chimeric influenza virus hemagglutinin (HA) polypeptide comprising one or more stem domain sequences, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and / or H5 subtype HA (H5 HA), fused with one or more globular head domain sequences, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).SELECTED DRAWING: None

The invention discloses an immunogenic composition containing nanoparticles as well as a preparation method and application of the immunogenic composition. The immunogenic composition is prepared from self-assembled gE nano-particles, saponin QS-21 and a neutral liposome, wherein the self-assembled gE nano-particles are self-assembled gE nano-particles; the self-assembled gE nanoparticles are formed by polymerizing and assembling monomers; the monomer comprises a VZV gE, a connecting peptide 1 (SGS), a VZV gI polypeptide containing a Th epitope, a connecting peptide 2 (GSGSG) and an influenza virus hemagglutinin Th epitope. The immunogenic composition can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is higher than that of Xinanliei, the use of an immunopotentiator can be reduced, and the clinical side reaction is lower; the vaccine can also induce an obvious gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. The immunogenic composition has good clinical application potential.

The invention provides a monoclonal antibody or an antibody fragment thereof, wherein the monoclonal antibody or the antibody fragment thereof is combined with a hemagglutinin stem region (HA stem region) of an influenza A virus.

The present invention relates to the field of animal health. Particularly, the present invention relates to a composition, comprising a modified Duck Enteritis Virus (DEV) which comprises and is capable of expressing a heterologous polynucleotide coding for a modified Hemagglutinin (HA) protein of avian influenza virus type H9 (AIV H9 HA protein) having amino acid substitution (s) relative to SEQ ID NO:1, and the use thereof.

Provided herein are isolated variant influenza hemagglutinin polypeptides, methods for providing isolated variant influenza hemagglutinin polypeptides, methods of using isolated variant influenza hemagglutinin polypeptides as diagnostic agents or for isolating antibodies, compositions comprising same, vaccines comprising same, and methods of their use, particularly in the detection, prevention, and / or treatment of influenza.

The present invention provides new canine Influenza H3N2 vaccines, including multivalent vaccines. The present invention provides an alphavirus RNA replicon particle that encodes a Canine Influenza (CIV) H3N2 hemagglutinin (HA) antigen. The present invention further provides methods of making and using the vaccines.

The application discloses a broad-spectrum affinity peptide ligand for influenza vaccine separation and purification and application thereof. The broad-spectrum affinity peptide ligand contains an amino acid sequence which is combined with the conserved structural units 130-loop, 150-loop and 190-helix of the hemagglutinin receptor binding site of an influenza virus, and the amino acid sequence is R 1 -R 2 -R 3 -(R 4 )3-R 5 -(R 4 )2-R 6 -R 7 -R 8 , R 1 is any one of glutamic acid, arginine, histidine and proline, R 2 is tryptophan, R 3 is any one of tyrosine and phenylalanine, R 4 is glycine, R 5 is any one of tryptophan, tyrosine and phenylalanine, R 6 is any one of glutamic acid, histidine, glutamine and tyrosine, R 7 is any one of tryptophan and phenylalanine, and R 8 is proline. The broad-spectrum affinity peptide ligand has high broad-spectrum affinity, and the broad-spectrum affinity chromatography medium can obtain the influenza vaccine with high purity and yield, and has great potential in application to the separation and purification process of the influenza vaccine.

The present invention provides compositions comprising one or more polynucleotides that encode a neuraminidase (NA) polypeptide and a hemagglutinin (HA) polypeptide separated by a furin cleavage site and a self-cleaving 2A polypeptide. Methods of using these compositions to induce an immune response to influenza in a subject are also provided.

Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

A universal influenza mRNA vaccine is provided, the protein encoded by the universal influenza mRNA vaccine consists of the extracellular domain (M2e), hemagglutinin (HA) stem LAH region, and nucleoprotein (NP) of the influenza A virus matrix protein 2. Furthermore, the application of the universal influenza mRNA vaccine in a mouse animal model is further provided, the universal influenza mRNA vaccine can induce a robust humoral and cellular immune response, protecting mice in the animal model from infection by multiple influenza A viruses. The universal influenza mRNA vaccine is safe, effective, and has a rapid production platform.

The present invention provides a fusion protein which is useful as a vaccine antigen against infectious diseases. A fusion protein including (a) a combination of hemagglutinin and an N-terminal domain of SARS-COV-2, (b) a combination of PspA and a receptor binding domain of SARS-COV-2, (c) a combination of hemagglutinin and respiratory syncytial virus G protein, or (d) a combination of PspA and hemagglutinin, is useful as a vaccine antigen against infectious diseases.